Drug patents revoked in 2024
Drug patents revoked in 2024 at the European Patent Office (EPO)
| Patent Number | Patent Title | Company | Revoked Date | Oppositions |
|---|---|---|---|---|
| EP2800476B1 | Method Of Feeding | DUPONT NUTRITION BIOSCIENCES APS |
Mar, 2024
|
NOVOZYMES
|
| EP3003360B1 | High Potency Pancreatin Pharmaceutical Compositions | ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD |
Mar, 2024
|
CAMULON
|
| EP3338784B1 | Human Milk Oligosaccharides For Modulating Inflammation | ABBOTT LABORATORIES |
Mar, 2024
|
NUTRICIA
SOCIT DES PRODUITS NESTL
|
| EP3174889B1 | Sofosbuvir In Crystalline Form And Process For Its Preparation | HC PHARMA |
Feb, 2024
|
KELTIE
|
| EP2658549B1 | Methods For Reducing The Incidence Of Oxidative Stress Using Human Milk Oligosaccharides, Vitamin C And Anti-Inflammatory Agents | ABBOTT LABORATORIES |
Feb, 2024
|
NUTRICIA
SOCIT DES PRODUITS NESTL
|
| EP3138564B1 | Nalmefene For Reduction Of Alcohol Consumption In Specific Target Populations | H LUNDBECK |
Feb, 2024
|
ALFRED E TIEFENBACHER
|
| EP3047843B1 | First Agent For Oxidation Hair Dye And Method For Stabilizing Color Tone Of Oxidation Hair Dyeing Agent Composition | HOYU |
Feb, 2024
|
KAO GERMANY
|
| EP2768322B1 | Whey Protein Micelles Against Muscle Atrophy And Sarcopenia | SOCIT DES PRODUITS NESTL |
Feb, 2024
|
ARLA FOODS AMBA
FRESENIUS KABI DEUTSCHLAND
|
| EP2359858B1 | Nutritional Composition Comprising Indigestible Oligosaccharides | NUTRICIA NV |
Feb, 2024
|
FRIESLANDCAMPINA NEDERLAND
NESTL HEALTH SCIENCE DEUTSCHLAND NESTL NUTRITION
|
| EP3257500B1 | Apixaban Formulations | BRISTOL MYERS SQUIBB IRELAND UNLIMITED |
Feb, 2024
|
GENERICS UK
INTAS PHARMACEUTICALS
KRKA
KUTZENBERGER WOLFF & PARTNER
MEDICHEM
SANDOZ
STADA ARZNEIMITTEL
TEVA PHARMACEUTICAL INDUSTRIES
ZAKLADY FARMACEUTYCZNE POLPHARMA
ZENTIVA KS
|
| EP2926802B1 | Hair Colouring Compositions, Kits, Method, And Use Thereof | NOXELL CORP |
Jan, 2024
|
LOREAL
|
| EP3251660B1 | Apixaban Formulations | BRISTOL MYERS SQUIBB IRELAND UNLIMITED |
Jan, 2024
|
GENERICS UK
INTAS PHARMACEUTICALS
KRKA
KUTZENBERGER WOLFF & PARTNER
MEDICHEM
SANDOZ
STADA ARZNEIMITTEL
TEVA PHARMACEUTICAL INDUSTRIES
ZAKLADY FARMACEUTYCZNE POLPHARMA
ZENTIVA KS
|
| EP2787078B1 | Antigen-Binding Molecule Having Regulated Conjugation Between Heavy-Chain And Light-Chain | CHUGAI PHARMACEUTICAL CO LTD |
Jan, 2024
|
STRAWMAN
|
| EP3017811B1 | Apixaban Formulations | BRISTOL MYERS SQUIBB IRELAND UNLIMITED |
Jan, 2024
|
GENERICS UK
HAMM&WITTKOPP PATENTANWLTE PARTMBB
INTAS PHARMACEUTICALS
KRKA
SANDOZ
STADA ARZNEIMITTEL
TEVA PHARMACEUTICAL INDUSTRIES
ZAKLADY FARMACEUTYCZNE POLPHARMA
ZENTIVA
|
| EP3031466B1 | Purified Amphiphilic Peptide Compositions And Uses Thereof | 3D MATRIX INC |
Jan, 2024
|
ARCH THERAPEUTICS
|
| EP2694049B1 | Tapentadol For Preventing Chronification Of Pain | GRUENENTHAL GMBH |
Jan, 2024
|
GENERICS UK
HEXAL
|
| EP3019180B1 | Beta-Casein A2 And Reducing Or Preventing Symptoms Of Lactose Intolerance | THE A MILK |
Jan, 2024
|
NUTRICIA
|
| EP2196189B1 | Cosmetic Sunscreen Compositions Based On Synergistic Filter Mixture And Their Use | LOREAL SA |
Jan, 2024
|
COHAUSZ & FLORACK PATENT UND RECHTSANWLTE PARTNERSCHAFTSGESELLSCHAFT MBB
STADA ARZNEIMITTEL
|
| EP3294270B1 | Pharmaceutical Composition Containing Rifaximin Alpha&Delta | SANDOZ AG |
Jan, 2024
|
ALFASIGMA
ALFRED E TIEFENBACHER
|
| EP3102605B1 | Combination Of A Pd-1 Antagonist And A Vegfr Inhibitor For Treating Cancer | MERCK SHARP AND DOHME LLC |
Jan, 2024
|
KNIG SZYNKA TILMANN VON RENESSE
WITHERS & ROGERS
|